ARCHIVES

FDA Approves Velcade For Treatment Of Refractory Multiple Myeloma

This article is from The Cancer Letter archive.

Vol. 26 No. 5 | May 30, 2003

Download PDF Visit The Full Archive

Related Articles

Organ Systems Support Contract To Cost More than OSCC Grant

September 30, 1988

Statement Defining Cancer Control Goals, Approaches Okayed By Board

February 6, 1981

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

Blueprint Group co-chairman Mark Ratain says group seeks “the perfect peer review system,” but a member’s email questions the proposal.

August 13, 2004

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008

In Brief: Angel Bradley, NCAB Member, Dies; Three State Colorectal Cancer Screening Effort Big Success

July 5, 1985